

ALN-4324 (GRB14) Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Type 2 diabetes mellitus ¹
MoA	Designed to target production of growth factor receptor-bound protein (GRB14) in the liver ²
Route of Administration	Subcutaneous ³

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting  Safety and Tolerability of Single Ascending Doses of ALN-4324 Healthy Volunteers³	ALN-4324; placebo	Safety (frequency of AEs up to 9 months)
Phase 2	Treatment Arms	Primary Endpoint
Recruiting  Safety, Tolerability, Efficacy, PK, and PD of Multiple Doses of ALN-4324 Adult overweight to obese patients with T2DM³	ALN-4324; placebo	Safety (frequency of AEs up to 12 months)

The safety and efficacy of ALN-4324 has not been established by any health authority.

AE, adverse event; GRB14, growth factor receptor-bound protein 14; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference; T2DM, type 2 diabetes mellitus. 1. Alnylam Pharmaceuticals, Inc. 2025. <https://investors.alnylam.com/press-release?id=28716> (Accessed May 4, 2026). 2. Jadhav V. Presented at Alnylam R&D Day, February 25, 2025. 3. ClinicalTrials.gov. 2026. <https://clinicaltrials.gov/study/NCT06845202> (Accessed May 4, 2026).